Abstract：
OBJECTIVE: The aim of this study was to highlight recent developments in the medical and surgical management of corneal neovascularization (NV).
RESULTS: Improved understanding and diagnostic criteria among clinicians have led to advancements in the characterization of corneal NV and objective assessment of treatment response through ancillary imaging devices. Developments in corneal NV treatments, such as antivascular endothelial growth factor, fine needle diathermy, and photodynamic therapy, have improved treatment success rates and visual outcomes. More recent surgical treatment advancements include corneal cross-linking, endothelial keratoplasty, and mitomycin intravascular chemoembolization. Finally, a greater appreciation of the molecular pathogenesis and angiogenic factors involved in corneal NV has identified numerous potential targeted therapies in the future.
CONCLUSIONS: The management of corneal NV has evolved to include several standalone and combination medical and surgical options. Additionally, improvements in quantifying corneal NV and understanding its molecular basis have contributed to new management strategies with improved outcomes.
RESULTS: Improved understanding and diagnostic criteria among clinicians have led to advancements in the characterization of corneal NV and objective assessment of treatment response through ancillary imaging devices. Developments in corneal NV treatments, such as antivascular endothelial growth factor, fine needle diathermy, and photodynamic therapy, have improved treatment success rates and visual outcomes. More recent surgical treatment advancements include corneal cross-linking, endothelial keratoplasty, and mitomycin intravascular chemoembolization. Finally, a greater appreciation of the molecular pathogenesis and angiogenic factors involved in corneal NV has identified numerous potential targeted therapies in the future.
CONCLUSIONS: The management of corneal NV has evolved to include several standalone and combination medical and surgical options. Additionally, improvements in quantifying corneal NV and understanding its molecular basis have contributed to new management strategies with improved outcomes.
摘要：
目的：本研究的目的是强调角膜新生血管（NV）的医学和外科治疗的最新进展。
结果：临床医生对角膜NV的认识和诊断标准的提高导致了角膜NV的表征和通过辅助成像设备对治疗反应的客观评估的进步。角膜NV治疗的进展，如抗血管内皮生长因子，细针透热，光动力疗法,改善了治疗成功率和视觉结果。最近的手术治疗进展包括角膜交联，内皮角膜移植术,和丝裂霉素血管内化疗栓塞。最后,对角膜NV涉及的分子发病机制和血管生成因子的更多认识已经确定了未来许多潜在的靶向治疗.
结论：角膜NV的管理已经发展到包括几个独立的和组合的医疗和手术选择。此外,在角膜NV的量化和对其分子基础的理解方面的改进有助于新的治疗策略,改善结局.
结果：临床医生对角膜NV的认识和诊断标准的提高导致了角膜NV的表征和通过辅助成像设备对治疗反应的客观评估的进步。角膜NV治疗的进展，如抗血管内皮生长因子，细针透热，光动力疗法,改善了治疗成功率和视觉结果。最近的手术治疗进展包括角膜交联，内皮角膜移植术,和丝裂霉素血管内化疗栓塞。最后,对角膜NV涉及的分子发病机制和血管生成因子的更多认识已经确定了未来许多潜在的靶向治疗.
结论：角膜NV的管理已经发展到包括几个独立的和组合的医疗和手术选择。此外,在角膜NV的量化和对其分子基础的理解方面的改进有助于新的治疗策略,改善结局.
